Data Characteristics
Recombinant protein clinical trial pre-screening data originates from clinical research databases (e.g., ClinicalTrials.gov, European Medicines Agency EMA database), biomedical literature (PubMed, PMC), patent databases, and internal pharmaceutical company trial reports. Data update frequencies vary. Public databases typically update monthly or quarterly. Literature and patents are continuously published. Document structures are highly standardized. Data often exists as structured tables (e.g., CSV, JSON), unstructured text (e.g., PDF trial protocols, investigator brochures), and semi-structured data (e.g., XML clinical trial registration information). Fields cover subject recruitment criteria, exclusion criteria, dosage information, administration routes, side effects, and biomarker data. Units strictly follow international standards. For example, dosages are typically in mg or IU, time in days, weeks, months, and biomarker concentrations in ng/mL, µg/L.
Constraints from These Characteristics on Multi-Turn Conversations and Prompts
The highly structured and standardized nature of recombinant protein clinical trial pre-screening data enables the extraction and comparison of specific fields in multi-turn conversations. This also requires precise prompt design to avoid ambiguity. For example, the strictness of dosage and units requires prompts to accurately identify and differentiate mg/kg from mg to prevent confusion. Integrating multiple data sources means that conversations may require recalling information from different knowledge bases. This requires prompts to guide the model in cross-knowledge base queries. Different update frequencies imply the system needs a mechanism to indicate data timeliness. Prompts should instruct the model to include data sources and update dates in responses. The presence of unstructured text, such as complex logical descriptions in trial protocols, requires prompts to guide the model in deep semantic understanding to extract implicit recruitment or exclusion criteria.
Configuration Settings
| Configuration Item | Suggested Value | Rationale |
|---|---|---|
maxContext | 8192 tokens | Accommodates longer descriptive text in recombinant protein clinical trial protocols and multi-turn conversation history. |
Chunk size (Segment Length) | 800–1200 characters (characters) | Balances semantic completeness and recall efficiency, suitable for the paragraph structure of clinical trial documents. |
Recall count (Number of Retrieved Items) | Top 5 entries (top 5) | Considers the complexity of recombinant protein trials, requiring multiple pieces of information for cross-validation while controlling computational load. |
Similarity threshold (Similarity Threshold) | 0.78 | Clinical trial terminology demands high precision. A threshold that is too low may introduce irrelevant information; too high may miss relevant information. |
Rerank result count (Number of Reranked Items) | 3 entries (3 items) | Further refines the most relevant segments from the initial retrieval, improving the accuracy of the final answer. |
responseFormat | json_schema | Facilitates structured extraction of subject criteria, dosage information, etc., aiding downstream system processing and automation. |
Common Pitfalls
- The response format is natural language text instead of the expected JSON. This occurs due to inaccurate
json_schemadefinition or insufficient model guidance to follow the format. - In multi-turn conversations, the model fails to accurately associate the recombinant protein name mentioned in previous turns with subsequent queries about side effects. This happens when
maxContextis insufficient, leading to historical information truncation. - When querying specific dosages and administration routes, the model's results do not match expectations. This occurs when units in the knowledge base's relevant fields are inconsistent, and the prompt does not explicitly request unit conversion or standardization.
Verification Steps
- Perform multi-turn conversation tests for typical recombinant protein clinical trial pre-screening scenarios. Verify the model's ability to maintain and accurately associate key information like subject criteria and dosage across different turns.
- Examine the JSON structure returned in the AI conversation card. Confirm the accuracy of field names, data types, and values. Compare against the predefined
json_schemato ensure format consistency. - Randomly select complex queries from clinical trial pre-screening. Compare the model's answers with information in the original documents. Evaluate the extraction precision for recombinant protein-specific fields like dosage and administration routes.
- Simulate queries after different data update cycles. Verify whether the model correctly references the latest data or clearly indicates data timeliness.
The values provided are common starting points and should be measured against the reader's own samples.
Question material comes from public community discussions. Configuration values are common starting points and should be measured against your own samples. Verified on 2026-09-21.